Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: Necrosis vs. apoptosis

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 1289-1295

  Cory, Ann H ^a   Chen, Jianming ^a   Cory, Joseph G ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Apoptosis; CDK; Drug resistance; Necrosis; p53; PI3; PRIMA 1

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2,2 BIS (HYDROXYMETHYL) 1 AZABICYCLO[2,2,2] OCTAN 3 ONE; ANTINEOPLASTIC AGENT; CASPASE 3; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; FLAVOPIRIDOL; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PRIMA 1; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; ENZYME ACTIVITY; LEUKEMIA; LEUKEMIA L 1210; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL CYCLE; CHROMONES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLAVONOIDS; LEUKEMIA L1210; MICE; MORPHOLINES; NECROSIS; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645814443     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bykov VJN, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Med 8: 282-288, 2002.
2. Bykov VJN, Issaeva N, Selivanova G and Wiman KG: Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 23: 2011-2018, 2002.
3. Bykov VJN, Selivanova G and Wiman KG: Small molecules that reactivate mutant p53. Eur J Cancer 39: 1828-1834, 2003.
4. Bykov VJN, Zache N, Stridh H, Westman J, Bergman J, Selivanova G and Wiman KG: PRIMA-1 met synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 24: 3484-3491, 2005.
5. Lehman NH, Mollgard L, Bengtzen S, Selivanova G, Wiman KG, Paul C and Merup M: Effects of PRIMA-1 on chronic lymphocytic leukemia cells with and without hemizygous p53 deletion. Br J Haematol 127: 285-291, 2004.
6. Myers MC, Wang J-L, Iera JA, Bang J-K, Hara T, Saito S, Zambetti GP and Appella DH: A new family of small molecules to probe the reactivation of mutant p53. J Am Chem Soc 127: 6152-6153, 2005.
7. Cory JC and Carter GL: Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors. Cancer Res 48: 839-843, 1988.
8. Carter GL and Cory JG: Selective resistance of L1210 cell lines to inhibitors directed at the individual subunits of ribonucleotide reductase. Advan Enzyme Regul 29: 123-139, 1989.
9. Carter GL and Cory JG: Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells. Cancer Res 48: 5796-5799, 1988.
10. Cory AH, Sato A, Thompson DP and Cory JG: Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor, 4-methyl-5-amino-1-formyl-isoquinoline thiosemicarbazone. Oncology Res 8: 449-456, 1996.
11. Krishan A: A rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66: 188-193, 1975.
12. He AWR and Cory JG: Effect of ionizing radiation on wild-type and mutant mouse leukemia L1210 cells. Oncol Res 10: 453-464, 1988
13. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
14. Sherr CJ: Tumor surveillance via the ARF-p53 pathway. Genes Dev 12: 2984-2991, 1998.
15. Giaceia AJ and Kastan MB: The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12: 2973-2983, 1998.